Kamada .(US:KMDA) Financial Modeling Prep·2026-03-11 23:00Group 1 - Kamada Ltd. is a global biopharmaceutical company focused on developing treatments for rare and serious conditions, operating in the Zacks Medical - Biomedical and Genetics industry [1] - Stifel Nicolaus has set a price target of $11 for Kamada, indicating a potential upside of 28.73% from its current price of $8.54 [1][6] - Kamada reported a fourth-quarter profit of $0.06 per share, which was below the Zacks Consensus Estimate of $0.09 per share, marking a 30.8% negative surprise [2][6] Group 2 - The company generated $44.68 million in revenue for the quarter ending December 2025, which was 2.29% below the Zacks Consensus Estimate but an improvement from $39.01 million in the same period the previous year [3] - For the full year 2025, Kamada achieved a record revenue of $180.5 million, marking a 12% increase compared to the previous year, with adjusted EBITDA rising by 23% to $42 million and net income surging by 40% to $20.2 million [3] - Looking forward, Kamada projects revenues between $200 million and $205 million for 2026, alongside an adjusted EBITDA ranging from $50 million to $53 million, indicating continued double-digit organic growth [4][6] Group 3 - Kamada's stock is currently trading at $8.54, reflecting a decrease of 4.69% or $0.42, with a market capitalization of approximately $492.6 million [5] - The stock has traded between a low of $8.41 and a high of $8.70 today, and over the past year, it has reached a high of $9.35 and a low of $5.54 [5]